查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1523301

纤维肌发育不良治疗市场报告：2030 年趋势、预测与竞争分析

Fibromuscular Dysplasia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

纤维肌性发育不良治疗的趋势与预测

预计 2024 年至 2030 年，全球纤维肌性发育不良治疗市场将以 7.3% 的复合年增长率成长。该市场的主要驱动因素是全球人口中高血压发病率的增加和吸烟率的上升。全球纤维肌性发育不良治疗市场的未来看起来充满希望，医院药局、零售药局和线上药局市场充满机会。

纤维肌性发育不良治疗的细分趋势

包含按药物类别、通路和地区分類的全球纤维肌性发育不良治疗预测。

纤维肌发育不良治疗市场洞察

Lucintel 预测，血管收缩素II 受体拮抗剂预计将在预测期内达到最高成长。

医院药房仍然是市场上最大的部分。

预计北美地区在预测期内将出现最高的成长。

常问问题

Q1.市场成长预测是多少：

A1. 2024 年至 2030 年，全球纤维肌性发育不良治疗市场预计将以 7.3% 的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 该市场的主要驱动因素是全球人口中高血压发病率的增加和吸烟率的上升。

Q3.市场的主要细分市场是：

A3. 纤维肌性发育不良治疗市场的未来性广阔，医院药局、零售药局、网路药局市场都有机会。

Q4.市场的主要企业是：

A4. 生产纤维肌性发育不良治疗药物的主要企业如下：

  • ALVOGEN
  • Aspen Surgical Products
  • AstraZeneca
  • B. Braun Melsungen
  • Bayer Healthcare Pharmaceuticals
  • Becton
  • Dickinson & Company
  • Pfizer
  • Sanofi-Aventis
  • Smith & Nephew

Q5.未来最大的细分市场是什么？

A5.Lucintel 预测，医院药局将在预测期内达到最高成长。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 预计北美地区在预测期内将出现最高成长。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章全球纤维肌性发育不良治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球纤维肌发育不良治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类别分類的全球纤维肌发育不良治疗市场
    • 血管张力素转化酵素抑制剂
    • 血管收缩素II受体阻断剂
    • 利尿剂
    • 钙离子通道阻断剂
    • β阻断剂
  • 按分销管道分類的全球纤维肌发育不良治疗市场
    • 医院药房
    • 零售药房
    • 网路药房

第四章 2018-2030年区域市场趋势及预测分析

  • 全球纤维肌发育不良治疗市场（按地区）
  • 北美纤维肌性发育不良治疗市场
  • 欧洲纤维肌性发育不良治疗市场
  • 亚太地区纤维肌发育不良治疗市场
  • 其他区域纤维肌发育不良治疗市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按药物类别分類的全球纤维肌发育不良治疗市场成长机会
    • 全球纤维肌发育不良治疗市场成长机会（按分销管道）
    • 全球纤维肌发育不良治疗市场按地区成长机会
  • 全球纤维肌性发育不良治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球纤维肌发育不良治疗市场的产能
    • 全球纤维肌性发育不良治疗市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • ALVOGEN
  • Aspen Surgical Products
  • AstraZeneca
  • B. Braun Melsungen
  • Bayer Healthcare Pharmaceuticals
  • Becton
  • Dickinson & Company
  • Pfizer
  • Sanofi-Aventis
  • Smith & Nephew
简介目录

Fibromuscular Dysplasia Treatment Trends and Forecast

The future of the global fibromuscular dysplasia treatment market looks promising with opportunities in the hospitals pharmacies, retail pharmacies, and online pharmacies markets. The global fibromuscular dysplasia treatment market is expected to grow with a CAGR of 7.3% from 2024 to 2030. The major drivers for this market are increasing incidence of hypertension across the global population and rising occurrence of smoking.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Fibromuscular Dysplasia Treatment by Segment

The study includes a forecast for the global fibromuscular dysplasia treatment by drug class, distribution channel, and region.

Fibromuscular Dysplasia Treatment Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Angiotensin-Converting Enzyme Inhibitors
  • Angiotensin II Receptor Blockers
  • Diuretics
  • Calcium Channel Blockers
  • Beta-Blockers
  • Others

Fibromuscular Dysplasia Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Fibromuscular Dysplasia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Fibromuscular Dysplasia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies fibromuscular dysplasia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the fibromuscular dysplasia treatment companies profiled in this report include-

  • ALVOGEN
  • Aspen Surgical Products
  • AstraZeneca
  • B. Braun Melsungen
  • Bayer Healthcare Pharmaceuticals
  • Becton
  • Dickinson & Company
  • Pfizer
  • Sanofi-Aventis
  • Smith & Nephew

Fibromuscular Dysplasia Treatment Market Insights

Lucintel forecasts that angiotensin II receptor blockers is expected to witness the highest growth over the forecast period.

Within this market, hospitals pharmacies will remain the largest segment.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Fibromuscular Dysplasia Treatment Market

Market Size Estimates: Fibromuscular dysplasia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Fibromuscular dysplasia treatment market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Fibromuscular dysplasia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, distribution channels, and regions for the fibromuscular dysplasia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the fibromuscular dysplasia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for fibromuscular dysplasia treatment market?

Answer: The global fibromuscular dysplasia treatment market is expected to grow with a CAGR of 7.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the fibromuscular dysplasia treatment market?

Answer: The major drivers for this market are increasing incidence of hypertension across the global population and rising occurrence of smoking.

Q3. What are the major segments for fibromuscular dysplasia treatment market?

Answer: The future of the fibromuscular dysplasia treatment market looks promising with opportunities in the hospitals pharmacies, retail pharmacies, and online pharmacies markets.

Q4. Who are the key fibromuscular dysplasia treatment market companies?

Answer: Some of the key fibromuscular dysplasia treatment companies are as follows:

  • ALVOGEN
  • Aspen Surgical Products
  • AstraZeneca
  • B. Braun Melsungen
  • Bayer Healthcare Pharmaceuticals
  • Becton
  • Dickinson & Company
  • Pfizer
  • Sanofi-Aventis
  • Smith & Nephew

Q5. Which fibromuscular dysplasia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that hospitals pharmacies is expected to witness the highest growth over the forecast period.

Q6. In fibromuscular dysplasia treatment market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.7 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the fibromuscular dysplasia treatment market by drug class (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, calcium channel blockers, beta-blockers, and others), distribution channel (hospitals pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Fibromuscular Dysplasia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Fibromuscular Dysplasia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Fibromuscular Dysplasia Treatment Market by Drug Class
    • 3.3.1: Angiotensin-Converting Enzyme Inhibitors
    • 3.3.2: Angiotensin II Receptor Blockers
    • 3.3.3: Diuretics
    • 3.3.4: Calcium Channel Blockers
    • 3.3.5: Beta-Blockers
  • 3.4: Global Fibromuscular Dysplasia Treatment Market by Distribution Channel
    • 3.4.1: Hospitals Pharmacies
    • 3.4.2: Retail Pharmacies
    • 3.4.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Fibromuscular Dysplasia Treatment Market by Region
  • 4.2: North American Fibromuscular Dysplasia Treatment Market
    • 4.2.1: North American Fibromuscular Dysplasia Treatment Market by Drug Class: Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Diuretics, Calcium Channel Blockers, Beta-Blockers, and Others
    • 4.2.2: North American Fibromuscular Dysplasia Treatment Market by Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Fibromuscular Dysplasia Treatment Market
    • 4.3.1: European Fibromuscular Dysplasia Treatment Market by Drug Class: Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Diuretics, Calcium Channel Blockers, Beta-Blockers, and Others
    • 4.3.2: European Fibromuscular Dysplasia Treatment Market by Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Fibromuscular Dysplasia Treatment Market
    • 4.4.1: APAC Fibromuscular Dysplasia Treatment Market by Drug Class: Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Diuretics, Calcium Channel Blockers, Beta-Blockers, and Others
    • 4.4.2: APAC Fibromuscular Dysplasia Treatment Market by Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Fibromuscular Dysplasia Treatment Market
    • 4.5.1: ROW Fibromuscular Dysplasia Treatment Market by Drug Class: Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Diuretics, Calcium Channel Blockers, Beta-Blockers, and Others
    • 4.5.2: ROW Fibromuscular Dysplasia Treatment Market by Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Fibromuscular Dysplasia Treatment Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Fibromuscular Dysplasia Treatment Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Fibromuscular Dysplasia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Fibromuscular Dysplasia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Fibromuscular Dysplasia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Fibromuscular Dysplasia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: ALVOGEN
  • 7.2: Aspen Surgical Products
  • 7.3: AstraZeneca
  • 7.4: B. Braun Melsungen
  • 7.5: Bayer Healthcare Pharmaceuticals
  • 7.6: Becton
  • 7.7: Dickinson & Company
  • 7.8: Pfizer
  • 7.9: Sanofi-Aventis
  • 7.10: Smith & Nephew